- Home
- OUSTZ vs GRI Comparison
OUSTZ vs GRI Comparison
Compare OUSTZ & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OUSTZ
- GRI
- Stock Information
- Founded
- OUSTZ N/A
- GRI 2018
- Country
- OUSTZ United States
- GRI United States
- Employees
- OUSTZ N/A
- GRI N/A
- Industry
- OUSTZ Industrial Machinery/Components
- GRI Biotechnology: Pharmaceutical Preparations
- Sector
- OUSTZ Industrials
- GRI Health Care
- Exchange
- OUSTZ Nasdaq
- GRI Nasdaq
- Market Cap
- OUSTZ 7.0M
- GRI 6.1M
- IPO Year
- OUSTZ N/A
- GRI N/A
- Fundamental
- Price
- OUSTZ $0.10
- GRI $0.72
- Analyst Decision
- OUSTZ
- GRI Strong Buy
- Analyst Count
- OUSTZ 0
- GRI 2
- Target Price
- OUSTZ N/A
- GRI $11.50
- AVG Volume (30 Days)
- OUSTZ N/A
- GRI 182.9K
- Earning Date
- OUSTZ N/A
- GRI 11-14-2024
- Dividend Yield
- OUSTZ N/A
- GRI N/A
- EPS Growth
- OUSTZ N/A
- GRI N/A
- EPS
- OUSTZ N/A
- GRI N/A
- Revenue
- OUSTZ N/A
- GRI N/A
- Revenue This Year
- OUSTZ N/A
- GRI N/A
- Revenue Next Year
- OUSTZ N/A
- GRI N/A
- P/E Ratio
- OUSTZ N/A
- GRI N/A
- Revenue Growth
- OUSTZ N/A
- GRI N/A
- 52 Week Low
- OUSTZ N/A
- GRI $0.30
- 52 Week High
- OUSTZ N/A
- GRI $65.00
- Technical
- Relative Strength Index (RSI)
- OUSTZ N/A
- GRI 44.58
- Support Level
- OUSTZ N/A
- GRI $0.68
- Resistance Level
- OUSTZ N/A
- GRI $0.77
- Average True Range (ATR)
- OUSTZ 0.00
- GRI 0.07
- MACD
- OUSTZ 0.00
- GRI -0.01
- Stochastic Oscillator
- OUSTZ 0.00
- GRI 16.44
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.